Table 1. Clinical characteristics and treatment outcomes in HIV-1/HBV co-infected Kenyan women.

Participant	Hepatitis BGenotype	HBeAg	HBV DNA Level(IU/mL)	Days to HBV DNA Suppressiona	Resistance Mutation	Total follow-uptime (months)	Maximum ALTb(U/L)	Mean Adherence (percent)c
1	Quantity n/sd	Negative	350	88	Below limite	33	36	100
2	A1	Negative	1,700	86	Below limit	37	34	92
3	A1	Negative	5,400	28	Below limit	71	20	98
4	A1	Negative	32,000	85	Below limit	38	11	98
5	A1	Negative	63,000	28	Below limit	10	11	100
6	A1	Positivef	2,700,000	87	Below limit	11	54	98
7g	A1	Positive	4,600,000	392	None	30	136	79
8	A1	Positive	290,000,000	262	None	51	14	97
9	A1	Positive	300,000,000	298	Noneh	17	51	95
10i	A1	Positive	490,000,000	Never suppressed	M204I	73	20	97
11j	A1	Positive	1,800,000,000	Never suppressed	None	27	14	88

HBeAg, hepatitis B e antigen. HBV, hepatitis B virus.

^aHBV DNA Suppression defined as ≤100 IU/mL.

^bUpper limit of normal for ALT assay is 17 U/L.

^cMean adherence calculated from pill count across all visits. If pill count unavailable, used patient recall of pills taken.

^dQuantity n/s, quantity not sufficient for baseline genotype analysis.

^eIf HBV DNA <100 IU/mL after 3 months, samples were below the limit for detection and sequencing was not performed.

^fThis woman seroconverted for HBeAg at day 87 of ART.

^gThis woman developed ALT elevations and had to discontinue ART at day 58; she resumed at day 334 and initially suppressed HBV DNA at day 392; she was noted to have poor adherence and HBV DNA relapse at day 456.

^hHad baseline mutation V173L.

ⁱThis woman developed the M204I lamivudine resistance mutation at day 392 of ART; the lowest HBV DNA level achieved was 1100 IU/mL at day 1320 of ART.

^jThis woman was noted to have poor adherence (88%); the lowest HBV DNA level achieved was 44,000 IU/mL at day 351 of ART.